Mr. Alex Blanchard reports

CARDIOVASCULAR PERFORMANCE IMPROVEMENTS INCLUDING LOWER BLOOD PRESSURE DISCOVERED FROM HUMAN CLINICAL TRIAL USING LEXARIA'S DEHYDRATECH(TM) POWERED TURBOCBD(TM) CAPSULES

Lexaria Bioscience Corp. has made additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study that evaluated TurboCBD, the company's proprietary, DehydraTech powered, cannabidiol (CBD) fortified hemp-oil capsule.

A single 90-milligram dose of TurboCBD provided evidence of lower blood pressure; higher blood flow to the brain; faster delivery onset of CBD into the bloodstream; and, larger quantities of CBD within the blood compared with a single 90 mg dose of generic CBD.

Key metabolic and hemodynamic performance findings linked to bioavailability enhancements were revealed in the study, which compared a 90 mg dose of Lexaria's TurboCBD with a 90 mg dose without Lexaria's DehydraTech technology (the positive control) as well as a placebo, as follows:

• Analysis of mean arterial blood pressure (MAP) at peak blood levels of CBD achieved with Lexaria's TurboCBD demonstrated a significant reduction in MAP compared with placebo (95 per cent CI; p is equal to 0.027). This finding was not observed with the dose-matched positive control formulation for which there was no significant decrease in MAP compared with placebo (95 per cent CI; p is equal to 0.625).
• Cerebral perfusion was also analyzed by an index of conductance in the middle cerebral artery (MCA). The findings revealed that Lexaria's TurboCBD caused the greatest increase in MCA conductance relative to both the positive control formulation and placebo (95 per cent CI; p is equal to 0.017 and P is equal to 0.002 respectively).
• Finally, over the six-hour study, analysis of the total area under the curve (AUC) demonstrated that Lexaria's TurboCBD resulted in a notable trend for higher levels of CBD in the bloodstream overall than the positive control formulation with total AUC of 10,865 6,322 observed with Lexaria's formulation compared to 7,115 ? 2,978 observed with the positive control (95 per cent CI; p is equal to 0.096).

Furthermore, when normalized to body mass, the AUC at the peak CBD concentration was markedly and significantly (95 per cent CI; p is equal to 0.02) higher with the TurboCBD 90 mg dose compared with the 90 mg dose positive control formulation.

On Aug. 1, 2018, the company reported data from this study that demonstrated much faster absorption of CBD in the subjects within the first 30 minutes of the study as well as higher bioavailability throughout the course of the study. The additional results announced today provide additional support for the pronounced effectiveness of Lexaria's DehydraTech technology at enabling superior cannabinoid delivery upon ingestion. The significant MAP results suggest potential utility of Lexaria's technology for CBD-induced reduction of blood pressure, while the enhanced MCA conductance also supports previous preclinical findings demonstrating the ability of Lexaria's technology to enhance drug delivery to the brain tissues as a principal site of action for compounds like cannabinoids.

"The findings that Lexaria's DehydraTech technology can enable superior cannabinoid delivery are unique in this healthy-human clinical trial. However, the findings that the technology can proffer a positive influence on blood pressure and perfusion to the brain are truly remarkable," said Prof. Philip Ainslie, PhD, principal investigator and co-director of the Centre for Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada. "The potential benefits of this approach, but over the acute and more chronic time periods, in more middle-aged or elderly populations should now be prioritized. Establishing the impact of CBD delivery on the health of the circulatory systems, including the brain, could have major implications for the adjunct treatment of high blood pressure and some neurological diseases."

The study also provided exploratory findings with respect to relative levels of several CBD liver metabolites that were analyzed for all subjects. Levels of 6?-OH-CBD, 7-OH-CBD, and 7-CBD-COOH were distinctly lower, albeit not statistically, initially in all cases and throughout the course of the study in two cases. These findings are aligned with Lexaria's theorized DehydraTech mechanism of action whereby it is believed to stimulate lymphatic drug uptake and routing to the systemic circulation bypassing liver metabolism to some degree as the basis for its rapid and pronounced effectiveness.

Based on the positive outcomes of this study, Lexaria intends to conduct further human clinical investigations within the next year using DehydraTech for cannabinoids with expanded numbers of subjects over a wider age range and selected pathologies. Additional data and reports will be provided from future studies as they become available.

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and outlicenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTech delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

We seek Safe Harbor.